secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2024-10-22T23:59:59+00:00
Accession:  0001193125-24-241114
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV gets FDA Accelerated Approval path for Viaskin Peanut patch in toddlers; cash $46.4M, going concern doubt
--------------------------------------------------------------------------------

- FDA confirmed Accelerated Approval pathway for Viaskin Peanut patch in 1-3 year-olds; COMFORT safety study (n=300-350) to start Q2 2025.
- VITESSE Phase 3 study in 4-7 year-olds enrolled 654 subjects; topline results expected Q4 2025.
- EMA scientific advice confirms MAA path for 1-7 year-old indication in Europe using the modified patch.
- Preliminary cash at Sep 30, 2024: $46.4M (down from $66.2M); Q3 net cash burn $19.8M.
- Substantial doubt about going concern; cash expected to fund operations only into Q1 2025; additional capital needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524241114/0001193125-24-241114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312524241114/d890731d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-241114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer